Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Glipizide Pharmacokinetics in Healthy and Diabetic Volunteers

Muhammad Atif¹ , Mahmood Ahmad², Qamar M uz-zaman², Muhammad Asif², Syed Azhar Syed Sulaiman¹, Asrul Akmal Shafie³, I Masood¹, Usman Minhas², Najam Us-saqib⁴

¹Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, University Sains Malaysia, 11800, Penang, Malaysia; ²Faculty of Pharmacy and Alternative Medicine, The Islamia University of Bahawalpur, Punjab, Pakistan; ³Discipline of Social and Administrative Pharmacy, School of Pharmaceutical Sciences, University Sains Malaysia, 11800, Penang, Malaysia; ⁴Ministry of Health, Government of Pakistan.

For correspondence:- Muhammad Atif Email: pharmacistatif@yahoo.com Tel:+6046566962

Received: 13 September 2010 Accepted: 15 February 2011 Published: 20 April 2011

Citation: Atif M, Ahmad M, uz-zaman QM, Asif M, Syed Sulaiman SA, Shafie AA, et al. Glipizide Pharmacokinetics in Healthy and Diabetic Volunteers. Trop J Pharm Res 2011; 10(2):147-152 doi: 10.4314/tjpr.v10i2.5

© 2011 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: Disease state may contribute to alteration in drug pharmacokinetics. The purpose of this study was to determine the effect of non-insulin dependent diabetes mellitus (NIDDM) on the pharmacokinetics of glipizide.

Methods: An open, single-dose, parallel design was applied to the study. Glipizide tablet (5 mg) was administered to healthy and diabetic human volunteers after over-night fast. Blood samples were collected, centrifuged and the plasma assayed using a sensitive and validated reverse phase high performance liquid chromatography (RP-HPLC) method. Various pharmacokinetic parameters were computed from the data obtained.

Results: The AUC_0-∞ values for healthy and diabetic volunteers was 1878 ± 195 and 1723 ± 138 ng.h/ml, respectively; these values were not significantly different (p > 0.05). The t_1/2for healthy volunteers was 3.04 ± 0.27 h while that for diabetic subjects was 2.98 ± 0.16 h. Clearance for healthy and diabetic volunteers was 0.59±0.06 and 0.64±0.05 ml/min/kg, respectively. These and other pharmacokinetic parameters assessed were not significantly different between healthy and diabetic volunteers (p > 0.05).

Conclusion: Although glipizide showed slightly more rapid clearance from the body of diabetic volunteers than from healthy volunteers, this difference, like those for other pharmacokinetic parameters, was not significant (p > 0.05).

Keywords: Glipizide, Bioavailability, Pharmacokinetics, Plasma, Reversed Phase-High performance liquid chromatography